Business Description
WuXi Biologics (Cayman) Inc
ISIN : KYG970081090
Compare
Compare
Traded in other countries / regions
02269.Hong KongWXXWY.USA1FW2.Germany2269.Mexico IPO Date
2017-06-13Description
WuXi Biologics (Cayman) Inc is principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. It provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.69 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 1 | |||||
| Interest Coverage | 39.03 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.18 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 52 | |||||
| 3-Year EBITDA Growth Rate | 60.9 | |||||
| 3-Year EPS without NRI Growth Rate | 59.5 | |||||
| 3-Year FCF Growth Rate | 47.2 | |||||
| 3-Year Book Growth Rate | 36.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 21.73 | |||||
| Future 3-5Y Total Revenue Growth Rate | 27.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.07 | |||||
| 9-Day RSI | 49.79 | |||||
| 14-Day RSI | 49.69 | |||||
| 6-1 Month Momentum % | -18.74 | |||||
| 12-1 Month Momentum % | -14.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | |||||
| Quick Ratio | 1.95 | |||||
| Cash Ratio | 1.07 | |||||
| Days Inventory | 81.98 | |||||
| Days Sales Outstanding | 112.11 | |||||
| Days Payable | 30.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.9 | |||||
| Shareholder Yield % | -0.07 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 41.5 | |||||
| Operating Margin % | 28.34 | |||||
| Net Margin % | 25.06 | |||||
| ROE % | 11.38 | |||||
| ROA % | 8.19 | |||||
| ROIC % | 10.55 | |||||
| ROC (Joel Greenblatt) % | 18.14 | |||||
| ROCE % | 12.18 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 41.66 | |||||
| Forward PE Ratio | 23.39 | |||||
| PE Ratio without NRI | 41.66 | |||||
| Price-to-Owner-Earnings | 184.4 | |||||
| PEG Ratio | 0.65 | |||||
| PS Ratio | 10.42 | |||||
| PB Ratio | 4.47 | |||||
| Price-to-Tangible-Book | 4.76 | |||||
| Price-to-Operating-Cash-Flow | 25.17 | |||||
| EV-to-EBIT | 32.41 | |||||
| EV-to-Forward-EBIT | 21.54 | |||||
| EV-to-EBITDA | 32.41 | |||||
| EV-to-Forward-EBITDA | 19.33 | |||||
| EV-to-Revenue | 9.94 | |||||
| EV-to-Forward-Revenue | 6.44 | |||||
| EV-to-FCF | 145.58 | |||||
| Price-to-Projected-FCF | 62.43 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.55 | |||||
| Price-to-Graham-Number | 2.97 | |||||
| Price-to-Net-Current-Asset-Value | 49.1 | |||||
| Earnings Yield (Greenblatt) % | 3.07 | |||||
| Forward Rate of Return (Yacktman) % | 18.79 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
WuXi Biologics (Cayman) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 18,291.635 | ||
| EPS (TTM) (HK$) | 1.049 | ||
| Beta | 1.48 | ||
| Volatility % | 71.69 | ||
| 14-Day RSI | 49.69 | ||
| 14-Day ATR (HK$) | 1.784727 | ||
| 20-Day SMA (HK$) | 43.3125 | ||
| 12-1 Month Momentum % | -14.9 | ||
| 52-Week Range (HK$) | 35 - 77.4 | ||
| Shares Outstanding (Mil) | 4,248.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WuXi Biologics (Cayman) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
WuXi Biologics (Cayman) Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
WuXi Biologics (Cayman) Inc Frequently Asked Questions
What is WuXi Biologics (Cayman) Inc(HKSE:02269)'s stock price today?
The current price of HKSE:02269 is HK$43.70. The 52 week high of HKSE:02269 is HK$77.40 and 52 week low is HK$35.00.
When is next earnings date of WuXi Biologics (Cayman) Inc(HKSE:02269)?
The next earnings date of WuXi Biologics (Cayman) Inc(HKSE:02269) is 2024-03-22 Est..
Does WuXi Biologics (Cayman) Inc(HKSE:02269) pay dividends? If so, how much?
WuXi Biologics (Cayman) Inc(HKSE:02269) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers